FDA guidance
M9 Biopharmaceutics Classification System-Based Biowaivers
FDA guidance · Final · issued May 11, 2021
Key facts
| Title | M9 Biopharmaceutics Classification System-Based Biowaivers |
|---|---|
| Status | Final |
| Issue date | May 11, 2021 |
| Center | Center for Drug Evaluation and Research |
| Issuing office | Center for Biologics Evaluation and Research, Center for Drug Evaluation and Research |
| Communication type | Guidance Document |
| Regulated product | Drugs |
| Docket number | FDA-2018-D-3614 |
| Open for comment | No |
| Document on fda.gov | fda.gov |
At a glance
- None Product codes referenced
- None Recognized standards referenced
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA guidance documents
FDA guidance documents describe the agency's current thinking on regulatory topics. Drafts are issued for comment before a final version is published.
Source: U.S. Food and Drug Administration (FDA), Guidance Documents